ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 327

Tolerogenic Dendritic Cells Ameliorates the Disease Severity of Murine Collagen-Induced Arthritis

Bin Ning1, Shang-You Yang2, Jianlu Wei1, Weiming Gong1 and Paul H. Wooley2, 1Orthopaedic Surgery, Shandong University Jinan Central Hospital, Jinan, China, 2Orthopaedic Research Institute, Via Christi Wichita Hospitals, Wichita, KS

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: animal models and rheumatoid arthritis, Dendritic cells, rheumatoid arthritis, treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis: Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis (RA) is a common autoimmune disease characterized by synovial inflammation, cartilage breakdown and bone destruction with the involvement of various types of cells including dendritic cells (DCs). A subset of dendritic cells that induce tolerance is called tolerogenic DCs (tolDCs). They may represent a promising immunosuppressive therapeutic tool for the attenuation of pathogenic T cell responses in autoimmune arthritis. In this study, we examine a series of stable antigen-specific tolDCs with tracking green fluorescent protein (GFP) to investigate their influence in the murine collagen induced arthritis (CIA) model.

Methods: The DCs were isolated from bone marrow of DBA/1Lac/J mice, and stimulated with IL-10 (10ng/ml), TGF-β (10ng/ml), and type II Collagen (CII) to induce CII-specific tolerogenic dendritic cells (tolDCs). The cells were then infected with Lenti-GFP viral vectors for GFP transduction. The GFP-tolDCs were injected ip into CIA mice at the time of arthritis onset. Arthritic animals were clinically assessed 3 times a week. The arthritic paws and blood specimens were harvested at 8 weeks after onset for histological, immunological and molecular analyses.

Results: The phenotype of tolDCs was confirmed by flow cytometry and ELISA.  Lymphocyte proliferation assays resulted in semi-matured, high IL-10 and TGF-β production, and low lymphocyte stimulatory capacity with low IFN-γ secretion. Both clinical and histological assessment on the animal studies indicated that the mice receiving tolDCs transfusion had a rapid and significant reduction in severity of arthritis compared to the controls (P<0.01). Fluorescent microscope observation showed aggregated green fluorescent cells in the inflamed synovial membrane where only sporadic presence in liver, spleen or lungs. Data also indicated the extended high expression levels of IL-10 and TGF-β at 4 weeks after the treatment, whereas the IL-17 expression was lower than controls (P < 0.01).

Conclusion: This study reports the successful establishment of a stable phenotype of CII-specific tolDCs and its potential therapeutic influence on collagen-induced arthritis in mice. Introduction of GFP-tolDCs significantly ameliorates the clinical and pathological progress of the experimental arthritis. TolDCs were cumulative at the inflammatory joints and the treatment diminished Th17 response (IL-17 expression). Further investigation is due to reveal the mechanism of tolDCs in regulation of the progression of rheumatoid arthritis.


Disclosure:

B. Ning,
None;

S. Y. Yang,
None;

J. Wei,
None;

W. Gong,
None;

P. H. Wooley,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tolerogenic-dendritic-cells-ameliorates-the-disease-severity-of-murine-collagen-induced-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology